|
||||
Statement on the President’s Cancer Panel Regarding Links Between Environmental Agents and CancerDALLAS — May
6, 2010 — Susan G. Komen for the Cure®, the world’s
leading breast cancer organization, today issued the following statement
on the President’s Cancer Panel on the links between environmental
agents and cancer:
“As long as society has been able to
identify and diagnose cancer, we’ve tried to find the definitive answers
about what causes this disease. It’s a tough issue and the answers are
not clear-cut,” said Elizabeth Thompson, senior vice president of
Medical and Scientific Affairs for Susan G. Komen for the Cure. “We
welcome this effort by the President’s Cancer Panel – we need all hands
on deck.” Komen continues to be a leader in this area by investing $50 million of its $450 million research portfolio into prevention, with another $20 million earmarked for 2010, including a landmark study underway with the Institute of Medicine specifically on environmental issues in breast cancer. Susan G. Komen for the Cure® is the world’s leading breast cancer organization, investing $1.5 billion in research and community programs over 30 years to end breast cancer forever. Breast Imaging Groups Recommend Mammograms at Age 40The Society of Breast Imaging and the Breast Imaging Commission of the American College of Radiology recommend that women at average risk of breast cancer begin screening with mammography starting at the age of 40. These recommendations were published in the Journal of the American College of Radiology. Mammograms (X-ray images of the breasts) are commonly used to screen women for breast cancer. The goal of screening mammography is to reduce breast cancer mortality by detecting breast cancer at an early stage. The age at which mammographic screening should begin has recently been a subject of debate. The American Cancer Society continues to recommend that women at average risk of breast cancer begin mammographic screening at the age of 40.[1] The U.S. Preventive Services Task Force, however, recently recommended against routine mammographic screening of women in their 40s, noting that the decision to begin screening women in this age group “should be an individual one and take patient context into account, including the patient's values regarding specific benefits and harms.”[2] Two other groups that have recently added their voices to the discussion are the American College of Radiology and the Society of Breast Imaging.[3] These groups continue to recommend that women at average risk of breast cancer begin annual mammographic screening at the age of 40. The groups also note that women at high risk of breast cancer, such as those with certain BRCA1 or BRCA2 mutations, should begin screening at an earlier age, and should be screened with breast magnetic resonance imaging (MRI) in addition to mammography. In light of the recent debate concerning when to begin screening mammography, women are encouraged to talk with their physician about the screening approach that’s right for them. References: [1] American Cancer Society. American Cancer Society responds to changes to USPSTF mammography guidelines. Available at: http://www.cancer.org/docroot/MED/content/MED_2_1x_American_Cancer_Society_Responds_to_Changes_to_USPSTF_Mammography_Guidelines.asp?sitearea=MED Accessed January 6, 2010. [2] U.S. Preventive Services Task Force. Screening for Breast Cancer. Available at: http://www.ahrq.gov/clinic/USpstf/uspsbrca.htm Accessed January 6, 2010. [3] Lee CH, Dershaw D, Kopans D et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. Journal of the American College of Radiology. 2010;7:18-27. Making Sense of New Mammography Recommendations11/17/09 - The U.S. Preventive Services Tasks Force (USPSTF) has reversed its position on screening mammography for women in their 40s: the group no longer recommends routine screening mammography for average-risk women in this age group.[1] The American Cancer Society, however, has stated that it will continue to recommend annual mammograms starting at the age of 40.[2] How should women respond to this news? Calmly. There has always been debate about whether or not to recommend routine screening mammography for women in their 40s. The focus of the debate is the balance of risks and benefits. The most important potential benefit of screening mammography is a modest reduction in breast cancer mortality. Potential risks of mammography include false-positive test results (which lead to stress and additional testing), false-negative test results (a missed cancer), and overdiagnosis. Overdiagnosis refers to the diagnosis of a cancer that will never cause health problems during the life of a patient. Overdiagnosis leads to unnecessary cancer treatment. For young women, the balance of risks and benefits is different than for older women, and may not clearly favor screening (although this point continues to be debated). Young women are more likely than older women to experience some of the downsides of mammographic screening, and are also less likely to have breast cancer. That fact that the USPSTF and the American Cancer Society now have different screening recommendations for women in their 40s simply reinforces the importance of educating yourself about the potential risks and benefits of screening, talking with your physician, and making the decision that’s right for you. This point is highlighted by the USPSTF, which notes “The decision to start regular, biennial screening mammography before the age of 50 years should be an individual one and take patient context into account, including the patient's values regarding specific benefits and harms.” The USPSTF statement is an update of its 2002 recommendations and is based on a review of the available data. Since 2002, new data have become available about mammography in younger women. Other highlights of the new USPSTF recommendations include the following:
Although the USPSTF’s position on breast self exams may also be perceived as controversial, there has never been clear evidence that breast self-exams reduce breast cancer mortality. It should be noted that the recent discussion regarding mammography recommendations is focused on women at average risk of breast cancer. Women at increased risk as a result of family or personal history may need to begin screening at a younger age, and may benefit from screening with breast magnetic resonance imaging (MRI) in addition to mammography. Women who have questions about the screening schedule and approach that’s right for them are advised to talk with their physician. References: [1] U.S. Preventive Services Task Force. Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine. 2009;151:716-726. [2] American Cancer Society. American Cancer Society responds to changes to USPSTF mammography guidelines. Available at: http://www.cancer.org/docroot/MED/content/MED_2_1x_American_Cancer_Society_Responds_to_Changes_to_USPSTF_Mammography_Guidelines.asp?sitearea=MED Accessed November 17, 2009.
Metastatis Gene Discovered by Komen-Funded Research Part of Nearly $53 million in Research Susan G. Komen for the Cure® Has Devoted To Metastatic Disease In Last Four Years A single gene that appears to play a crucial role in aggressive breast cancers by both increasing the ability of the cancer to spread and making it resistant to chemotherapy has been discovered by a team of researchers funded, in part, by a Susan G. Komen for the Cure® research grant. Scientists used innovative approaches that combine sophisticated new tests and traditional experimental techniques to detect the gene called MTDH, which appears to be involved in more than a third of all breast cancers. Not only did these researchers identify the gene, they were able to identify how this gene helps tumors spread. Now they believe drugs could be developed that block the gene -- keeping local tumors from metastasizing or spreading. This is significant because 98 percent of patients with breast cancer that has not spread beyond the breast live five years or more, while only 27 percent of patients whose cancer has spread to other organs survive five years. The important discovery was reported in the January 6 issue of Cancer Cell by Yibin Kang, Ph.D., of Princeton University, and colleagues. Komen for the Cure provided Kang with a two-year $250,000 grant in 2005. For more information on Komen-funded research, please visit http://www.komen.org/. |
||||
|
||||
|